|
solutions was €144.6 million, which grew 22% and increased 23% on an organic basis, driven by growth in standard syringes and cartridges, and included variable compensation tied to GLP therapies. In the third quarter of 2026, gross profit increased by €8.9 million, and gross profit margin grew 10 basis points to 32.1%. This was driven by higher revenue, the combined improvements in Fishers and Latina and a better mix, which was offset by higher utilities and depreciation costs. Operating profit margin grew 90 basis points to 23%. In the third quarter of 2026, revenue from the Engineering Segment decreased 12% to €32 million, primarily due to lower sales in pharma visual inspection, and assembly and packaging, which offset growth in aftersales activities. In the third quarter of 2026, gross profit margin decreased 20 basis points to 10.2%, due to lower revenue, the timing of order intake and project execution. Cost optimization initiatives helped to improve operating profit margin by 220 basis points to 1.1%. Please turn to the next slide for a review of our balance sheet and cash flow. We ended the quarter with cash and cash equivalents of €114.9 million and net debt of €353.7 million. We believe we have adequate liquidity to fund our strategic priorities through a combination of cash on hand, available credit lines, cash generated from operations, and the ability to access additional financing. For the third quarter of 2026, capital expenditures totaled €44.8 million, mostly related to growth investments in the new plants, and for our device programs in Germany. In the third quarter of 2026, net cash from operating activities totaled €57.6 million. Cash used in property, plant, and equipment, and intangible assets was €36.3 million. In the third quarter of 2026, the company generated free cash flow of €21.7 million. |